CytoMed Therapeutics Limited (GDTC)

2.0200 -0.1300 (-6.05%) As of 10:18AM EDT. Market open.

CytoMed Therapeutics Limited

1 Commonwealth Lane, No. 08-22
Singapore 149544
Singapore
65 6250 7738
https://w2.cytomed.sg

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Chee Kong Choo	Executive Chairman	27.32k	N/A	1958
Dr. Wee Kiat Tan Ph.D.	CEO, COO & Director	88.13k	N/A	1988
Dr. Jieming Zeng M.D., Ph.D.	Chief Scientific & Medical Officer and Director	89.74k	N/A	1974
Ms. Yvonne Goh	Chief Financial Officer	N/A	N/A	1990
Dr. Tien Wee Luk M.D.	Chief Clinical Officer & Director	N/A	N/A	1986
Ms. Yoong Ying Tan	Chief Corporate Officer	N/A	N/A	1989

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

Corporate governance

CytoMed Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.